Search research articles
Contact Us
Filters
Showing results (201-210 of 323) with videos related to
Page
of 33
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 22, 2018
Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191
Haiwen Ni, Fazal Shirazi, Veerabhadran Baladandayuthapani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2019
Correction: Resveratrol Exerts Antiproliferative Activity and Induces Apoptosis in Waldenström Macroglobulinemia
Aldo M Roccaro, Xavier Leleu, Antonio Sacco, et al.
British Journal of Haematology
|
December 22, 2015
Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study
Jorge J Castillo, Shirley D'Sa, Michael P Lunn, et al.
American Journal of Hematology
|
January 17, 2020
CXCR4 mutational status does not impact outcomes in patients with Waldenström macroglobulinemia treated with proteasome inhibitors
Jorge J Castillo, Joshua N Gustine, Kirsten Meid, et al.
British Journal of Haematology
|
November 19, 2025
Repurposing pacritinib to target MYD88-mutated Waldenström macroglobulinaemia
Shirong Liu, Amanda Kofides, Xia Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 10, 2009
Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180
Steven P Treon, Leukothea Ioakimidis, Jacob D Soumerai, et al.
Blood
|
May 4, 2007
Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism
Evdoxia Hatjiharissi, Lian Xu, Daniel Ditzel Santos, et al.
Leukemia & Lymphoma
|
May 3, 2008
Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia
Xavier Leleu, Anne-Sophie Moreau, Edie Weller, et al.
Blood
|
February 26, 2017
Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia
Lian Xu, Nicholas Tsakmaklis, Guang Yang, et al.
Haematologica
|
November 12, 2009
IgA and IgG hypogammaglobulinemia in Waldenström's macroglobulinemia
Zachary R Hunter, Robert J Manning, Christine Hanzis, et al.
Page
of 33
Search research articles
Search
Showing results (201-210 of 323) with videos related to
Sort By:
Page
of 33
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 22, 2018
Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191
Haiwen Ni, Fazal Shirazi, Veerabhadran Baladandayuthapani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2019
Correction: Resveratrol Exerts Antiproliferative Activity and Induces Apoptosis in Waldenström Macroglobulinemia
Aldo M Roccaro, Xavier Leleu, Antonio Sacco, et al.
British Journal of Haematology
|
December 22, 2015
Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study
Jorge J Castillo, Shirley D'Sa, Michael P Lunn, et al.
American Journal of Hematology
|
January 17, 2020
CXCR4 mutational status does not impact outcomes in patients with Waldenström macroglobulinemia treated with proteasome inhibitors
Jorge J Castillo, Joshua N Gustine, Kirsten Meid, et al.
British Journal of Haematology
|
November 19, 2025
Repurposing pacritinib to target MYD88-mutated Waldenström macroglobulinaemia
Shirong Liu, Amanda Kofides, Xia Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 10, 2009
Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180
Steven P Treon, Leukothea Ioakimidis, Jacob D Soumerai, et al.
Blood
|
May 4, 2007
Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism
Evdoxia Hatjiharissi, Lian Xu, Daniel Ditzel Santos, et al.
Leukemia & Lymphoma
|
May 3, 2008
Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia
Xavier Leleu, Anne-Sophie Moreau, Edie Weller, et al.
Blood
|
February 26, 2017
Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia
Lian Xu, Nicholas Tsakmaklis, Guang Yang, et al.
Haematologica
|
November 12, 2009
IgA and IgG hypogammaglobulinemia in Waldenström's macroglobulinemia
Zachary R Hunter, Robert J Manning, Christine Hanzis, et al.
Page
of 33